Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (hepatocytes) | 0.10 |
| chemistry Open Targets | a small-molecule pocket: ancrod, plasminogen, alfimeprase +2 | 0.60 |
| trials ClinicalTrials.gov | 8 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 36 Parkinson's papers of 1,998 | 0.53 |
| pathways Reactome | 22 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 10166
Sealed predictions
- FGA in dopamine neurons, braak+0.44 (p 0.237) → +0.47 (p 0.206)receipt 10172
Swarm cases
receipt 10172: FGA in dopamine neurons, braak
- power
- full sample +0.38 (p 0.123, n 18), 95% CI -0.11 to +0.72. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.38 (p 0.118, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.47 (p 0.049, n 18). not the mix.
- skeptic
- leave-one-out range +0.30 to +0.50, sign flips 0; without severely affected donors +0.38 (p 0.123, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FGA in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts